Clinical trial
A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
NCT04308395 is registered in ClinicalTrials.gov with Sol-Gel Technologies, Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
- Lead sponsor
- Sol-Gel Technologies, Ltd.
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- June 3, 2020
- Completion date
- July 14, 2021
- Enrollment
- 108 (actual)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.